Literature DB >> 9402170

Effect of age on the characteristics and clinical behavior of non-Hodgkin's lymphoma patients. The Non-Hodgkin's Lymphoma Classification Project.

.   

Abstract

BACKGROUND: The goals of this study are to describe the frequency, clinical characteristics, and outcome of the different non-Hodgkin's lymphomas according to age. PATIENTS AND METHODS: Patients included in the recently published analysis of the Non-Hodgkin's Lymphoma Classification Project were analyzed. All patients had their slides reviewed and classified by five independent expert hematopathologists. Lymphomas were classified according to the Revised European American Classification of lymphoid neoplasms. Sufficient data were available on 1283 cases. Five age groups were analyzed: < 35 years, 35-49 years, 50-59 years, 60-69 years, and > or = 70 years.
RESULTS: Few differences were observed between the age groups with regard to lymphoma types and clinical characteristics. Anaplastic large cell lymphoma, Burkitt's lymphoma, and lymphoblastic lymphoma were observed more frequently in patients younger than 35 years, whereas small lymphocytic and lymphoplasmacytoid lymphomas were observed more frequently in patients older than 70 years. Mantle cell lymphoma and marginal zone lymphomas were observed more frequently in middle-aged patients. Poor performance status was more frequent in older patients, as was bone marrow infiltration, whereas spleen involvement was more frequent in younger patients. Young and older patients had a slightly worse age-adjusted International Prognostic Index score (P < 0.01). Complete response rates decreased with age from 68% in the youngest patients to 45% in the oldest patients (P < 0.0001). Median event-free survival and overall survival also decreased with age (P < 0.0001).
CONCLUSIONS: Elderly patients have a poorer outcome than younger patients but age alone is not sufficient to discriminate patients with a poor outcome. However, the histologic type of lymphoma and clinical characteristics may define a subgroup of patients with a poor outcome in each age category.

Entities:  

Mesh:

Year:  1997        PMID: 9402170

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  21 in total

1.  Senior adult oncology.

Authors:  Arti Hurria; Ilene S Browner; Harvey Jay Cohen; Crystal S Denlinger; Mollie deShazo; Martine Extermann; Apar Kishor P Ganti; Jimmie C Holland; Holly M Holmes; Mohana B Karlekar; Nancy L Keating; June McKoy; Bruno C Medeiros; Ewa Mrozek; Tracey O'Connor; Stephen H Petersdorf; Hope S Rugo; Rebecca A Silliman; William P Tew; Louise C Walter; Alva B Weir; Tanya Wildes
Journal:  J Natl Compr Canc Netw       Date:  2012-02       Impact factor: 11.908

2.  Rituximab and CHOP chemotherapy plus GM-CSF for previously untreated diffuse large B-cell lymphoma in the elderly: a Wisconsin oncology network study.

Authors:  Julie E Chang; Songwong Seo; Kyungmann M Kim; Jae E Werndli; Wayne A Bottner; Gilberto A Rodrigues; Federico A Sanchez; Thomas J Saphner; Walter L Longo; Brad S Kahl
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2010-10

Review 3.  Treatment of diffuse large B-cell lymphoma in the elderly: strategies integrating oncogeriatric themes.

Authors:  Pieternella J Lugtenburg; Pieter Sonneveld
Journal:  Curr Oncol Rep       Date:  2008-09       Impact factor: 5.075

4.  Diffuse large B-cell lymphoma in adults aged 75 years and older: a single institution analysis of cause-specific survival and prognostic factors.

Authors:  Stephen D Smith; Andy Chen; Stephen Spurgeon; Craig Okada; Guang Fan; Jennifer Dunlap; Rita Braziel; Richard Maziarz
Journal:  Ther Adv Hematol       Date:  2013-12

5.  Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin's lymphoma.

Authors:  Mayumi Mori; Kiyoshi Kitamura; Michihiko Masuda; Tomomitsu Hotta; Tamotsu Miyazaki; Akira B Miura; Hideaki Mizoguchi; Akira Shibata; Hidehiko Saito; Tamotsu Matsuda; Toru Masaoka; Mine Harada; Yoshiyuki Niho; Fumimaro Takaku
Journal:  Int J Hematol       Date:  2005-04       Impact factor: 2.490

6.  Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis.

Authors:  Paul A Hamlin; Sacha Satram-Hoang; Carolina Reyes; Khang Q Hoang; Sridhar R Guduru; Sandra Skettino
Journal:  Oncologist       Date:  2014-10-23

7.  Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.

Authors:  Bertrand Coiffier; Catherine Thieblemont; Eric Van Den Neste; Gérard Lepeu; Isabelle Plantier; Sylvie Castaigne; Sophie Lefort; Gérald Marit; Margaret Macro; Catherine Sebban; Karim Belhadj; Dominique Bordessoule; Christophe Fermé; Hervé Tilly
Journal:  Blood       Date:  2010-06-14       Impact factor: 22.113

8.  Low expression of dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin in non-Hodgkin lymphoma and a significant correlation with β2-microglobulin.

Authors:  Dongbing Ding; Wenbin Chen; Changfu Zhang; Zhe Chen; Yanmei Jiang; Ziyi Yang; Xudong Jiang; Yunfei Zuo; Shuangyi Ren
Journal:  Med Oncol       Date:  2014-09-03       Impact factor: 3.064

9.  A case of T/null anaplastic large cell lymphoma arising in lung.

Authors:  Zenaida Cerimagić; Safet Guska; Bedrudin Banjanović
Journal:  Bosn J Basic Med Sci       Date:  2006-08       Impact factor: 3.363

10.  Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611).

Authors:  Michael Tallarico; Jared C Foster; Drew Seisler; Jacqueline M Lafky; Arti Hurria; Aminah Jatoi; Harvey J Cohen; Hyman B Muss; Nancy Bartlett; Bruce D Cheson; Sin-Ho Jung; John P Leonard; John C Byrd; Chadi Nabhan
Journal:  J Geriatr Oncol       Date:  2018-04-17       Impact factor: 3.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.